Delving into the Latest Updates on Zhejiang Zova Biotherapeutics,Inc. with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Digestive System Disorders

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	5

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	2
EGFR(Epidermal growth factor receptor erbB1)	1
5T4 x Tubulin	1

主要目的： 1.评估ZV0203在表达HER2的晚期实体瘤受试者中的安全性和耐受性 2.确定ZV0203的最大耐受剂量（MTD）或2期推荐剂量（RP2D）次要目的： 1.评估ZV0203、总抗体和Duo-5的药代动力学（PK）特征 2.评估ZV0203的初步抗肿瘤活性 3.确定ZV0203的免疫原性探索性目的：探讨肿瘤HER2状态和对ZV0203的临床反应之间的关系。

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of ZV0203 in subjects with advanced solid tumors expressing HER2 2. To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ZV0203 Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of ZV0203, total antibody, and Duo-5 2. To evaluate the preliminary anti-tumor activity of ZV0203 3. To determine the immunogenicity of ZV0203 Exploratory objectives: To explore the relationship between tumor HER2 status and clinical response to ZV0203.

Start Date17 Dec 2021

Sponsor / Collaborator

Zhejiang Hisun Pharmaceutical Co., Ltd.

[+2]

100 Clinical Results associated with Zhejiang Zova Biotherapeutics,Inc.

Login to view more data

0 Patents (Medical) associated with Zhejiang Zova Biotherapeutics,Inc.

Login to view more data

100 Deals associated with Zhejiang Zova Biotherapeutics,Inc.

Login to view more data

100 Translational Medicine associated with Zhejiang Zova Biotherapeutics,Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 1 Clinical

2

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ZV203 ( HER2 )	-	Phase 1
ADC-2122 ( HER2 )	HER2 Positive Solid Tumors More	Phase 1
Recombinant humanized anti-EGFR mAb-DUO-5 conjugate(Zova Biotherapeutics/Zhejiang Hisun Pharmaceutical) ( EGFR )	Neoplasms More	Preclinical
Antibody-drug conjugate(Zova Biotherapeutics)	Liver Cancer More	Discovery
ZV-0501 ( 5T4 x Tubulin )	Ovarian Cancer More	Discovery